Evaluation of Antiproliferative Effect of N-(alkyladamantyl)phthalimides In vitro

Chemical Biology and Drug Design

Volumn 79, Issue 4, 2012, Pages 497-506

  Horvat, Margareta ^a   Uzelac, Lidija ^a   Marjanović, Marko ^a   Cindro, Nikola ^a   Franković, Oliver ^a   Mlinarić Majerski, Kata ^a   Kralj, Marijeta ^a   Basarić, Nikola ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Adamantanes; Antiproliferation; Biological screening; Phthalimides; Structure based drug design

Indexed keywords

ANTINEOPLASTIC AGENT; N [3 (1 ADAMANTYL)PROPYL]PHTHALIMIDE; N(1 ADAMANTYL) 3 AMINOPHTHALIMIDE; N(1 ADAMANTYL) 3 NITROPHTHALIMIDE; N(2 ADAMANTYL) 3 AMINOPHTHALIMIDE; N(2 ADAMANTYL) 3 NITROPHTHALIMIDE; N(4 HOMOADAMANTYL)PHTHALIMIDE; N(4 PROTOADAMANTYL)PHTHALIMIDE; N[3 (2 ADAMANTYL)PROPYL]PHTHALIMIDE; PHTHALIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HCT116; CELL STRAIN MCF 7; COLON CARCINOMA; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; LEUKEMIA CELL; PRIORITY JOURNAL; SUBSTITUTION REACTION;

ADAMANTANE; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; PHTHALIMIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858796176     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01305.x     Document Type: Article

References (36)

1. Teo S.K. (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J;7:E14-E19.
2. Eleutherakis-Papaiakovou V., Bamias A., Dimopoulos M.A. (2004) Thalidomide in cancer medicine. Ann Oncol;15:1151-1160.
3. Gupta S. (2002) A decision between life and death during TNF-alpha induced signaling. J Clin Immunol;22:185-194.
4. Fujita M., Hirayama T., Ikeda N. (2002) Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of tumor necrosis factor α production. Bioorg Med Chem;10:3113-3122.
5. Shibata Y., Sasaki K., Hashimoto Y., Iwasaki S. (1996) Phenylphthalimides with tumor necrosis factor alpha production-enhancing activity. Chem Pharm Bull;44:156-162.
6. Kok S.H.L., Gambari R., Chui C.H., Yuen M.C.W., Lin E., Wong R.S.M., Lau F.Y. et al. (2008) Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. Bioorg Med Chem;16:3626-3631.
7. Fort R.C. Jr. (1976) Adamantane. The Chemistry of Diamond Molecules. New York: Marcel Dekker Inc; p. 327-357.
8. Vamecq J., Van Derpoorten K., Poupaert J.H., Balzarini J., De Clercq E., Stables J.P. (1998) Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity - preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl)substitution for antiviral properties. Life Sci;63:PL267-PL274.
9. Orzeszko A., Gralewska R., Starościak B.J., Kazimierczuk Z. (2000) Synthesis and antimicrobial activity of new adamantane derivatives I. Acta Biochim Polonica;47:87-94.
10. Orzeszko A., Kamińska B., Orzeszko G., Starościak B.J. (2000) Synthesis and antimicrobial activity of new adamantane derivatives II. Il Farmaco;55:619-623.
11. Orzeszko A., Lasek W., Świtaj T., Stoksik M., Kamińska B. (2003) Tumor necrosis factor-alpha production regulating activity of phthalimide derivatives in genetically modified murine melanoma cells B78H1. Il Farmaco;58:371-376.
12. Shibata Y., Shichita M., Sasaki K., Nishimura K., Hashimoto Y., Iwasaki S. (1995) N-alkylphthalimides: structural requirement of thalidomidal action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor α production by human leukemia HL-60 cells. Chem Pharm Bull;43:177-179.
13. Sasaki K., Shibata Y., Nishimura K., Hashimoto Y., Iwasaki S. (1994) Enhancement of 12-O-tetradecanoylphorbol-13-acetate induced tumor necrosis factor α production by phenyl phthalimide analogs. Bio Pharm Bull;17:1313-1315.
14. Shibata Y., Sasaki K., Nishimura K., Hashimoto Y., Iwasaki S. (1994) Enhancement of phorbol ester-induced production of tumor necrosis factor-α by 2, 6-dimethylphenylphthalimide. Bio Pharm Bull;17:1532-1534.
15. Tsuji M., Koiso Y., Takahashi H., Hashimoto Y., Endo Y. (2000) Modulators of tumor necrosis factor α production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. Bio Pharm Bull;23:513-516.
16. Cindro N., Horvat M., Mlinarić-Majerski K., Griesbeck A.G., Basarić N. (2011) Photoinduced homolytic C-H activation in N-(4-homoadamantyl)phthalimide. Beilstein J Org Chem;7:270-276.
17. Supek F., Kralj M., Marjanović M., Šuman L., Šmuc T., Krizmanić I., Žinić B. (2008) Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis. Invest New Drugs;26:97-110.
18. Gredičak M., Supek F., Kralj M., Majer Z., Hollosi M., Šmuc T., Mlinarić-Majerski K., Horvat Š. (2010) Computational structure-activity study directs synthesis of novel antitumor enkephalin analogs. Amino Acids;38:1185-1191.
19. Boyd M.R., Kenneth D.P. (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res;34:91-109.
20. Basarić N., Horvat M., Franković O., Mlinarić-Majerski K., Neudörfl J., Griesbeck A.G. (2009) Photoinduced hydrogen atom abstraction in N-(adamantyl)phthalimides: structure-reactivity study in the solid state. Tetrahedron;65:1438-1443.
21. Ohno M., Ishizaki K., Eguchi S. (1988) Synthesis of adamantane derivatives by bridgehead radical addition to electron-deficient unsaturated bonds. J Org Chem;53:1285-1288.
22. Schleyer P.v.R., Funke E., Liggero S.H. (1969) Homoadamantane. I. A new synthesis. Conformational evidence. Degenerate 4-homoadamantyl cation. J Am Chem Soc;91:3965-3967.
23. Schlatmann J.L.M.A., Korsloot J.G., Schut J. (1970) Synthesis of some 4-mono- and 4, 5-disubstituted homoadamantanes (tricyclo[4.3.1.13.8]undecanes). Tetrahedron;26:949-954.
24. Yamaguchi R., Kawanisi M. (1975) Photosensitized polar addition of acetic acid to 4-homoadamantene. Behavior of the 4-homoadamantyl cation. Bull Chem Soc Jpn;48:1296-1300.
25. Nordlander J.E., Wu F.Y.-H., Jindal S.P., Hamilton J.B. (1969) Acetolysis of 4-homoadamantyl tosylate. J Am Chem Soc;91:3962-3964.
26. Mlinarić-Majerski K., Majerski Z. (1973) Rearrangement of the 4-homoadamantyl cation. One-step preparation of 2, 6-trimethylenebicyclo[2.2.2]octane. Tetrahedron Lett;2:2.
27. Majerski Z., Hameršak Z. (1980) Rearrangement of bridgehead alcohols to polycyclic ketones by fragmentation-cyclization: 4-protoadamantanone. Org Synth;59:147-153.
28. Morgan S.E., Rackham D.M. (1981) Carbon-13 NMR spectra of some 4-substituted protoadamantanes. Org Magn Res;16:126-128.
29. Lenoir D., Schleyer P.V.R. (1970) Chemistry of 4-protoadamantyl derivatives. J Chem Soc D Chem Commun:941-942.
30. Lenoir D., Hall R.E., Schleyer P.V.R. (1974) Chemistry of protoadamantane. IV. Preparation and solvolysis of secondary 4-protoadamantyl esters. Relation to the solvolysis of 2-adamantyl derivatives. J Am Chem Soc;96:2138-2148.
31. Ng S.W., Gütschow M., Weiss M., Hauschildt S., Teubert U., Hecker T.K., Luzzio F.A., Kruger E.A., Eger K., Figg W.D. (2003) Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res;63:3189-3194.
32. Li P.-K., Pandit B., Sackett D.L., Hu Z., Zink J., Zhi J., Freeman D., Robey R.W., Werbovetz K., Lewis A., Li C. (2006) A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther;5:450-456.
33. Marks M.G., Shi J., Fry M.O., Xiao Z., Trzyna M., Pokala V., Ihnat M.A., Li P.-K. (2002) Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull;25:597-604.
34. Ural A.U., Avcu F., Zerman M., Yilmaz M.I., Pekel A., Beyzadeoglu M. (2006) Differentiating effect of thalidomide and GM-CSF combination on HL-60 acute promyelocytic leukemia cells. Exp Oncol;28:216-219.
35. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.-T., Treon S.P., Lin B., Schlossman R.L., Richardson P., Muller G., Stirling D.I., Anderson K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood;96:2943-2950.
36. Chapman J.M. Jr, Cocolas G.H., Hall I.H. (1983) Hypolipidemic activity of phthalimide derivatives IV: further chemical modification and investigation of the hypolipidemic activity of N-substituted imides. J Pharm Sci;72:1344-1347.